The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.

Autor: Özyurt N; Department of Medical Oncology, Ordu University School of Medicine, Ordu, Turkey., Alkan A; Department of Medical Oncology, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey. alkanali@yahoo.com.; Faculty of Medicine, Department of Medical Ongology, Mugla Sıtkı Koçman University, Kötekli Mh. Marmaris Yolu Bulvarı No: 55 Menteşe, Muğla, 48000, Turkey. alkanali@yahoo.com., Gülbağcı B; Department of Medical Oncology, Sakarya University School of Medicine, Sakarya, Turkey., Seyyar M; Department of Medical Oncology, Kocaeli University School of Medicine, İzmit, Turkey., Aydın E; Department of Medical Oncology, Karadeniz Technical University School of Medicine, Trabzon, Turkey., Şahbazlar M; Department of Medical Oncology, Celal Bayar University School of Medicine, Manisa, Turkey., Türker M; Department of Medical Oncology, Çukurova University School of Medicine, Adana, Turkey., Kınıkoğlu O; Department of Medical Oncology, Kartal Training and Research Hospital, İstanbul, Turkey., Yerlikaya T; Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey., Dinç G; Department of Medical Oncology, Okmeydanı Training and Research Hospital, İstanbul, Turkey., Aytaç A; Department of Medical Oncology, Aydın Adnan Menderes University School of Medicine, Aydın, Turkey., Kalkan Z; Department of Medical Oncology, Dicle University School of Medicine, Diyarbakır, Turkey., Ebinç S; Diyarbakır Training and Research Hospital, Department of Medical Oncology, Diyarbakır, Turkey., Gültürk İ; Department of Medical Oncology, Bakırköy Sadi Konuk Training and Research Hospital, İstanbul, Turkey., Keskinkılıç M; Department of Medical Oncology, Dokuz Eylül University School of Medicine, İzmir, Turkey., İşleyen ZS; Department of Medical Oncology, Bezm-i Alem Vakıf University School of Medicine, İstanbul, Turkey., Çağlayan D; Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey., Türkel A; Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey., Aydın E; Department of Medical Oncology, Recep Tayyip Erdoğan University School of Medicine, Rize, Turkey., Şakalar T; Department of Medical Oncology, Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaraş, Turkey., Sekmek S; Ankara Bilkent City Hospital, Department of Medical Oncology, Ankara, Turkey., Yıldırım N; Department of Medical Oncology, Fırat University School of Medicine, Elazığ, Turkey., Koçak S; Department of Medical Oncology, Koç University School of Medicine, İstanbul, Turkey., Okutur K; Department of Medical Oncology, İstanbul Arel University School of Medicine, İstanbul, Turkey., Özveren A; Department of Medical Oncology, Acıbadem Kent Hospital, İzmir, Turkey., Dursun B; Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey., Kitaplı S; Department of Medical Oncology, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey., Eren OÖ; Department of Medical Oncology, Selçuk University School of Medicine, Konya, Turkey., Beypınar İ; Department of Medical Oncology, Alanya Alaittin Keykubat University School of Medicine, Antalya, Turkey., Hacıbekiroğlu İ; Department of Medical Oncology, Sakarya University School of Medicine, Sakarya, Turkey., Çabuk D; Department of Medical Oncology, Kocaeli University School of Medicine, İzmit, Turkey., Karaman E; Department of Medical Oncology, Karadeniz Technical University School of Medicine, Trabzon, Turkey., Acar Ö; Department of Medical Oncology, Celal Bayar University School of Medicine, Manisa, Turkey., Paydaş S; Department of Medical Oncology, Çukurova University School of Medicine, Adana, Turkey., Eryılmaz MK; Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey., Demir B; Department of Medical Oncology, Aydın Adnan Menderes University School of Medicine, Aydın, Turkey., Oruç Z; Department of Medical Oncology, Dicle University School of Medicine, Diyarbakır, Turkey., Yılmaz M; Department of Medical Oncology, Bakırköy Sadi Konuk Training and Research Hospital, İstanbul, Turkey., Biricik FS; Department of Medical Oncology, Koç University School of Medicine, İstanbul, Turkey., Salim DK; Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey., Tanrıverdi Ö; Department of Medical Oncology, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey., Doğan M; Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Oct 09; Vol. 14 (1), pp. 23556. Date of Electronic Publication: 2024 Oct 09.
DOI: 10.1038/s41598-024-75293-5
Abstrakt: The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the study TNBC patients who were treated with neoadjuvant chemotherapy (NAC) and surgery were analyzed retrospectively. The primary aim of the study was to analyze the impact of Her2 status(Her2-0 and Her2-low) on pathological complete response (pCR). The secondary objectives were disease free survival (DFS) and overall survival (OS). 620 female triple negative breast cancer patients were evaluated. 427 patients (68.9%) had Her2-0 and 193(31.1%) had her2-low pathology. The pCR rates were similar between Her2-0 and Her2-low patients (33.0% vs. 27.5%, p = 0.098). Although Her2-0 group has better DFS (106 vs. 50 months, p = 0.002), in multivariate analysis it had a HR of 0.74 (p = 0.06). In addition, OS was similar (131 vs. 105 months, p = 0.13) with a HR of 0.88 (p = 0.61). In multivariate analysis; presence of LVI (HR:2.2 (95% CI 1.1-3.5) p = 0.001), Clinical stage T1/T2 (HR:0.39 (95% CI 0.2-0.6) p < 0.001) and lymph node negativity (HR:0.35 (95% CI 0.1-0.9) p = 0.03) were independent factors for OS. Although there were pathological and clinical differences, the pCR, DFS and OS were similar between Her2-0 and Her2-low TNBC patients. The importance of Her2 status of TNBC in neoadjuvant setting should be further studied.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: